Over the past decade, two factors have positively influenced genetic testing rates of patients with newly diagnosed ovarian cancer: the demonstrated efficacy of maintenance therapy with poly (ADP-ribose) polymerase inhibitors in germline BRCA1/2 carriers6,7 and recognition that family history–based testing criteria were frequently inadequate.8 Subsequently, genetic testing guidelines have been revised in many countries to include all women with ovarian cancer.9 There is, however, a legacy of untested, often deceased, patients whose diagnosis predated these changes. This evidence concerns the gene BRCA1 and ovarian carcinoma.